(Q44047791)

29 November 2017

Complete remission of recurrent glioblastoma multiforme following local infusions of lymphokine activated killer cells. Case report (English)

1 reference

29 November 2017

1 reference

H Naganuma

1

1 reference

29 November 2017

R Kimurat

2

1 reference

29 November 2017

A Sasaki

3

1 reference

29 November 2017

A Fukamachi

4

1 reference

29 November 2017

H Nukui

5

1 reference

29 November 2017

K Tasaka

6

1 reference

29 November 2017

1 January 1989

1 reference

29 November 2017

1 reference

29 November 2017

99

1 reference

29 November 2017

3-4

1 reference

29 November 2017

157-160

1 reference

https://scigraph.springernature.com/pub.10.1007/bf01402326

29 November 2017

0 references

cites work

Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells

1 reference

12 December 2020

In vitro cytolysis of primitive neuroectodermal tumors of the posterior fossa (medulloblastoma) by lymphokine-activated killer cells

1 reference

12 December 2020

Comparison of in vitro glioma cell cytotoxicity of LAK cells from glioma patients and healthy subjects.

1 reference

12 December 2020

Interleukin-2 and lymphokine activated killer (LAK) cells in the treatment of malignant glioma: clinical and experimental studies.

1 reference

12 December 2020

Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes

1 reference

12 December 2020

Adoptive immunotherapy of human meningeal gliomatosis and carcinomatosis with LAK cells and recombinant interleukin-2.

1 reference

12 December 2020

Interleukin-2 and autologous lymphokine-activated killer cells in the treatment of malignant glioma. Preliminary report.

1 reference

12 December 2020

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer

1 reference

12 December 2020

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

1 reference

12 December 2020

In vitro killing of human glioblastoma by interleukin-2-activated autologous lymphocytes

1 reference

12 December 2020

Interleukin-2 or autologous lymphokine-activated killer cell treatment of malignant glioma: phase I trial.

1 reference

12 December 2020

An adoptive immunotherapy of patients with medulloblastoma by lymphokine-activated killer cells (LAK).

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF01402326

1 reference

29 November 2017

1 reference